Appendix 4E & 2016 Full Year Statutory Accounts
Filed with ASX · · 76 pages · English
The loss after tax for FY16 was A$62,015,184 compared to A$32,151,696 in FY15. The increase was attributable to non-cash financing costs, including a share-based payment to a strategic investor (Ridgeback Capital Investments) and non-cash changes in the fair value of the financial liability. Removing the impact of those two non-cash items results in a loss after tax for FY16 of A$13,939,476. This
Earlier from Immutep
- European Patent Grants for IMP731 Antibody
- PRR Collaborates In New Clinical Trial For Imp321
- First Data From Phase IIb Clinical Trial of Imp321
- Prima BioMed Files U.S Shelf Registration Statement
- PRR Enters Agreement with Sydys to Advance CVac Program
Later from Immutep
- S&P DJ Indices Announces March Quarterly Rebalance
- S&P DJ Indices Announces March Quarterly Review
- Wuxi & Prima sign MOU for strategic partnership
- Prima receives UK approval for AIPAC study
- Prima announces AIPAC clinical trial data
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep